Orris

Explain blood transfusion reaction with detailed treatment

Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive, detailed content from multiple authoritative textbooks. Let me compose the full answer.

Blood Transfusion Reactions

Up to 20% of all transfusions result in some form of adverse reaction; most are minor, but some are life-threatening. Reactions are classified as acute (occurring during or within 24 hours of transfusion) or delayed (days to years later), and as noninfectious or infectious.

Universal First Steps for ANY Suspected Reaction

Regardless of the type suspected:
  1. Stop the transfusion immediately
  2. Keep the IV line open with normal saline
  3. Notify the physician to evaluate the patient
  4. Notify the blood bank — the blood bank physician is a critical resource
  5. Send a clerical check — confirm patient ID, unit label, blood type (the most common cause of severe hemolytic reaction is clerical error)
  6. Do not discard the blood bag — return it and recently transfused units to the blood bank
A common error is to abandon all future transfusions. Even patients with severe reactions can safely receive future blood products if correctly matched. — Tintinalli's Emergency Medicine, p. 1540

Incidence of Noninfectious Transfusion Reactions

ReactionRisk per Unit Transfused
Febrile nonhemolytic~1 : 1,100
Allergic~1 : 1,200
Allergic (severe)~1 : 15,500
Transfusion-associated circulatory overload (TACO)~1 : 9,000
Hypotensive reaction~1 : 32,000
Delayed hemolytic~1 : 32,000
Delayed serologic~1 : 8,000
TRALI~1 : 140,000
Acute hemolytic~1 : 110,000
TA-GvHD<1 : 10,000,000
— Goldman-Cecil Medicine, Table 162-2

1. Acute Hemolytic Transfusion Reaction (AHTR)

Mechanism

Preformed recipient antibodies bind transfused RBC antigens → antigen-antibody complex forms → complement cascade activation → intravascular hemolysis. Most commonly caused by ABO incompatibility (e.g., group A RBCs into a group O recipient). — Goldman-Cecil Medicine, p. 1845

Symptoms

  • Fever, chills, rigors
  • Low back pain, flank pain
  • Flushing, facial erythema
  • Dyspnea, tachycardia
  • Hypotension, shock
  • Hemoglobinuria (pink/red/dark urine) — a hallmark
  • Bleeding (DIC may develop)

Treatment

  1. Stop transfusion immediately
  2. Maintain IV access; begin IV saline hydration to maintain urine output (goal ≥ 1 mL/kg/hr)
  3. Diuretics (furosemide or mannitol) may be needed if oliguric
  4. Cardiorespiratory support as indicated (vasopressors for shock)
  5. Monitor for and treat DIC (fresh frozen plasma, cryoprecipitate, platelets as needed)
  6. Monitor urine output, BUN, creatinine for acute kidney injury

Workup

  • Retype and repeat crossmatch on new pretransfusion-style specimen
  • Direct Coombs test (DAT) — usually positive (antibody-coated RBCs); may be negative if hemolysis is severe and all coated RBCs are already destroyed
  • CBC, creatinine, PT/aPTT
  • Haptoglobin (decreased), LDH (elevated), indirect bilirubin (elevated), plasma free hemoglobin
  • Urine dipstick for hemoglobin + microscopy (hemoglobinuria without hematuria distinguishes it from hematuria) — Quick Compendium of Clinical Pathology, p. 90

2. Febrile Nonhemolytic Transfusion Reaction (FNHTR)

Mechanism

Rise in temperature ≥ 1°C, possibly with chills or rigors, occurring during or up to 1 hour after transfusion. Attributed to accumulation of pyrogenic cytokines in stored units, and/or antibodies against donor leukocytes.

Treatment

  1. Stop transfusion — cannot initially distinguish from hemolytic reaction
  2. Perform hemolytic workup (as above) to exclude AHTR or bacterial contamination
  3. Acetaminophen 325–500 mg to treat fever — diphenhydramine is commonly given but evidence shows no effect on febrile reactions
  4. Once hemolytic reaction and bacterial contamination are excluded, fever is self-limited (resolves within 2–3 hours)
  5. Restarting the unit is controversial — driven by clinical condition, severity, and rarity of the product
Prevention: Leukoreduced blood products reduce FNHTR by removing cytokine-producing leukocytes. — Henry's Clinical Diagnosis and Management, p. 882

3. Allergic Transfusion Reactions

Spectrum

  • Mild: Urticaria, pruritus, erythema, flushing
  • Severe/Anaphylactic: Hypotension, tachycardia, bronchospasm, stridor, loss of consciousness, shock, cardiac arrest

Mild Allergic Reaction — Treatment

  1. Stop transfusion
  2. Diphenhydramine 25–50 mg IV (antihistamine)
  3. If symptoms fully resolve, the transfusion may be restarted
  4. No further workup needed, but notify blood bank

Severe/Anaphylactic Reaction — Treatment

  1. Stop transfusion — do NOT restart
  2. Maintain IV access; supportive care
  3. Epinephrine (first-line for anaphylaxis):
    • SC: 0.3–0.5 mg (0.3–0.5 mL of 1:1,000 solution) — can repeat every 20–30 min for up to 3 doses
    • IV: 0.5 mg (5 mL of 1:10,000 solution) — repeat every 5–10 min for refractory hypotension
  4. Diphenhydramine 50–100 mg IV for cutaneous manifestations
  5. Oxygen; intubation if upper airway involvement
  6. IV fluids, Trendelenburg position for hypotension
  7. Aminophylline 6 mg/kg loading dose for bronchospasm
  8. Hydrocortisone 500 mg IV if symptoms persist (not effective acutely)
IgA deficiency: Patients with IgA deficiency who develop IgE anti-IgA antibodies can have anaphylactic reactions. Future transfusions should use IgA-deficient donors or washed cellular components. — Henry's Clinical Diagnosis and Management, p. 882–883

4. Transfusion-Related Acute Lung Injury (TRALI)

Mechanism

Noncardiogenic pulmonary edema occurring during or within 6 hours of transfusion. Caused by:
  • Donor HLA or granulocyte antibodies (in donor plasma, especially from multiparous female donors) binding recipient leukocytes → pulmonary capillary injury
  • Alternatively, lipid inflammatory mediators in stored blood activate primed recipient neutrophils

Symptoms

  • Acute dyspnea, hypoxemia (PaO₂/FiO₂ < 300)
  • Tachycardia, fever, hypotension
  • Bilateral pulmonary infiltrates on CXR (not along major vasculature as in cardiac failure)
  • No signs of cardiac failure — pulmonary artery wedge pressure NOT elevated
  • BNP does not rise (distinguishes from TACO)
  • Resolves within 48–96 hours in most cases; mortality ~10%

Treatment

  1. Stop transfusion; recover blood bags from recently transfused units
  2. Supplemental oxygen
  3. Mechanical ventilation if severely hypoxic
  4. Corticosteroids are of little value
  5. Diuretics are not indicated (no fluid overload; giving diuretics worsens hemodynamics)
  6. Notify blood bank for donor lookback/antibody testing — Henry's Clinical Diagnosis and Management, p. 883

5. Transfusion-Associated Circulatory Overload (TACO)

Mechanism

Congestive heart failure from volume overload, especially in patients with pre-existing cardiac or renal disease.

Symptoms

  • Dyspnea, orthopnea, cyanosis
  • Elevated blood pressure, tachycardia
  • Pulmonary edema, JVD, pedal edema
  • Elevated BNP (helps differentiate from TRALI)

Treatment

  1. Stop or slow transfusion
  2. Diuretics (furosemide) — mainstay of treatment
  3. Oxygen; upright positioning
  4. For recurrent TACO: use slower transfusion rate, split units, pre-transfusion diuretics

6. Bacterial Contamination

Key Points

  • More common with platelet components (stored at room temperature)
  • May cause high fever, rigors, rapid cardiovascular collapse, septic shock
  • Clinically may resemble AHTR

Treatment

  1. Stop transfusion immediately
  2. Obtain blood cultures from patient
  3. Send blood bag for Gram stain and culture
  4. Broad-spectrum IV antibiotics immediately (e.g., piperacillin-tazobactam or meropenem + vancomycin)
  5. IV fluid resuscitation and vasopressors for septic shock
  6. ICU admission if hemodynamically unstable

7. Delayed Hemolytic Transfusion Reaction (DHTR)

Mechanism

Occurs 3–10 days (sometimes up to weeks) after transfusion. An anamnestic alloantibody response in previously sensitized patients (prior transfusion or pregnancy) destroys transfused RBCs extravascularly. Common antibodies: Kidd (Jk), Duffy (Fy), Kell (K).

Symptoms

  • Unexpected fall in hemoglobin post-transfusion (less than expected rise)
  • Low-grade fever, chills, jaundice, malaise, back pain
  • Rare: renal failure

Treatment

  • Usually self-limiting; supportive care
  • For future transfusions: provide antigen-negative, crossmatch-compatible RBCs
  • Prophylactic RBC antigen matching is the primary prevention strategy
Hyperhemolytic variant (mainly in sickle cell disease/thalassemia): Destroys both donor AND recipient RBCs → severe anemia + reticulocytopenia. Treatment: erythropoietin, IVIG, corticosteroids, rituximab, tocilizumab, eculizumab under expert supervision. — Goldman-Cecil Medicine, p. 1847

8. Transfusion-Associated Graft-versus-Host Disease (TA-GvHD)

Mechanism

Viable donor lymphocytes engraft in immunosuppressed recipients → immune attack on host tissues. Unlike hematopoietic stem cell transplant GvHD, this has a nearly 100% fatality rate due to profound pancytopenia.

High-Risk Patients

  • Congenital immunodeficiencies
  • Hodgkin disease, acute leukemia
  • Recipients of directed donations from blood relatives
  • Stem cell transplant recipients

Symptoms

  • Pancytopenia (the fatal feature — marrow is attacked)
  • Erythematous rash / generalized erythroderma
  • Liver dysfunction (elevated LFTs)
  • GI symptoms (diarrhea, nausea, vomiting)

Treatment / Prevention

  • No effective treatment once established
  • Prevention: Gamma irradiation of cellular blood components for at-risk patients eliminates donor lymphocytes — Goldman-Cecil Medicine, p. 1847

9. Hypotensive Transfusion Reactions

  • Associated with bedside leukoreduction filters in patients on ACE inhibitors
  • Mechanism: generation of bradykinin → vasodilation
  • Treatment: Stop transfusion — typically resolves spontaneously
  • Prevention: use prestorage leukoreduction rather than bedside filters

10. Post-Transfusion Purpura (PTP)

  • Rare (1 : 10,000,000); typically in multiparous women or multiply transfused patients
  • Platelet antibodies (anti-HPA-1a) destroy both donor and recipient platelets
  • Presents as severe thrombocytopenia 5–10 days post-transfusion
  • Treatment: IVIG (first-line), plasmapheresis, corticosteroids

Summary Table: Acute Reactions and Management

ReactionKey FeatureImmediate ActionSpecific Treatment
Acute hemolyticHemoglobinuria, back pain, shockStop transfusionIV fluids, diuresis, DIC management
Febrile nonhemolyticFever ≥1°C, chillsStop; hemolytic workup firstAcetaminophen; self-limited
Mild allergicUrticaria, pruritusStop transfusionDiphenhydramine; may restart
AnaphylacticHypotension, bronchospasmStop; do NOT restartEpinephrine, airway management
TRALIBilateral infiltrates, hypoxia, no ↑BNPStop; return bagsO₂, ventilation; NO diuretics
TACOPulmonary edema, ↑BP, ↑BNPSlow/stop transfusionDiuretics, O₂
Bacterial contaminationHigh fever, rapid collapseStop; culturesBroad-spectrum IV antibiotics
HypotensiveHypotension onlyStop transfusionSelf-resolving
Sources:
  • Goldman-Cecil Medicine, pp. 1844–1848
  • Henry's Clinical Diagnosis and Management by Laboratory Methods, pp. 882–886
  • Tintinalli's Emergency Medicine, pp. 1539–1541
  • Quick Compendium of Clinical Pathology, 5th ed., pp. 89–91
This is a shared conversation. Sign in to Orris to start your own chat.